Get the Stockscreener App
225.00
14.21%
28.00
Moderna Inc stock is traded at $225.00, with a volume of 28.75M.
It is up +14.21% in the last 24 hours and up +65.92% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$197.00
Open:
$199
24h Volume:
28.75M
Relative Volume:
1.50
Market Cap:
$89.83B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-27.62
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
+18.41%
1M Performance:
+65.92%
6M Performance:
+338.77%
1Y Performance:
+717.29%
1-Day Range:
$197.17
$225.00
1-Week Range:
$182.50
$225.00
52-Week Range:
$22.28
$225.00
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-26 | Downgrade | Citigroup | Neutral → Sell |
| Sep-03-26 | Downgrade | Rothschild & Co Redburn | Neutral → Sell |
| Aug-28-26 | Upgrade | Argus | Hold → Buy |
| Aug-25-26 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Aug-19-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-19-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock? - Zacks Investment Research
Is Invesco S&P 500 Equal Weight ETF (RSP) a Strong ETF Right Now? - Zacks Investment Research
Form 4 Moderna Inc For: 7 October By Investing.com - Investing.com Canada
Moderna (MRNA) CFO has 704 shares withheld for taxes after converting a stock grant. - Stock Titan
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? - Zacks Investment Research
Moderna (MRNA) COO Juan Andres reports direct ownership of 125,000 common shares. - stocktitan.net
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026 - GlobeNewswire Inc.
Moderna (MRNA) Stock Dips While Market Gains: Key Facts - Zacks Investment Research
Moderna Inc (MRNA) Stock News & Articles - 24/7 Wall St.
Prediction: Moderna Stock Will Soar 100% by 2030 - The Motley Fool
Stock Market Midday, Sept. 30: Markets Rise on Softer Inflation Data, Investors Await Micron Earnings - The Motley Fool
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? - Zacks Investment Research
Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock? - The Motley Fool
Moderna stock at USD 198.88 on September 25, 2026, up 2.08 percent - AD HOC NEWS
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research
3 Bullish Setups for the Week Ahead - Zacks Investment Research
Moderna, Inc.Common Stock (NQ: MRNA - The Chronicle-Journal
Moderna, Inc.Common Stock (NQ: MRNA - The Chronicle-Journal
Moderna (MRNA) insider exercises options, sells 80K shares - stocktitan.net
Moderna, Inc.Common Stock (NQ: MRNA - The Chronicle-Journal
Another multimillion stock sale lined up for 2026 at Moderna (NASDAQ: MRNA) - stocktitan.net
Moderna (MRNA) CFO sells 34,836 shares under pre-set plan - stocktitan.net
Insider at Moderna (NASDAQ: MRNA) plans multimillion-dollar stock sale for 2026 - stocktitan.net
Top Biotech Stocks To Watch TodaySeptember 13th - MarketBeat
Promising Biotech Stocks To Keep An Eye OnSeptember 12th - MarketBeat
California State Teachers Retirement System Buys 27,274,128 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know - Yahoo Finance
Moderna stock gains after a 6.7 percent jump - ad-hoc-news.de
Healthcare Stocks To Keep An Eye OnSeptember 11th - MarketBeat
Moderna Inc Stock (MRNA) Moved Up by 8.63% on Sep 11: A Full Analysis - TradingKey
MRNA Looks 517.6% Overvalued on GF Value™ as Price-to-Sales Soars Amid Losses - GuruFocus
MRNA Stock Climbs As Analysts Back Oncology And Vaccine Push - StocksToTrade
MRNA Stock Climbs As Oncology Catalysts And Upgrades Pile Up - timothysykes.com
Moderna (NASDAQ:MRNA) Shares Up 6.7%Should You Buy? - MarketBeat
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know - The Globe and Mail
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know - tradingview.com
Best Biotech Stocks To Watch NowSeptember 11th - MarketBeat
Moderna climbs 8% as volatile trading continues (MRNA:NASDAQ) - Seeking Alpha
Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat - Yahoo Finance
Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat - 24/7 Wall St.
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report? - Zacks Investment Research
What to Know About the 2026–2027 COVID-19 Vaccines - Verywell Health
Frequency Electronics, ACV Auctions, HP And Other Big Stocks Moving Higher On Friday - benzinga.com
Why is Moderna stock rallying today? By Investing.com - Investing.com Canada
Why Is the Market Watching Moderna (MRNA)? - Kalkine Media
Amundi Reduces Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Rep. Maria Elvira Salazar Sells Moderna, Inc. (NASDAQ:MRNA) Stock - MarketBeat
Rep. Maria Elvira Salazar Acquires Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Congresswoman Bets on Elon Musk, Warren Buffett: Here’s the Latest Stock Transactions - TradingView
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moderna Inc Stock (MRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hoge Stephen | Officer |
Sep 15 '26 |
Proposed Sale |
146.07 |
40,281 |
5,883,709 |
0 |
| Hoge Stephen | President |
Sep 15 '26 |
Sale |
146.07 |
40,281 |
5,883,846 |
1,562,029 |
| Hoge Stephen | President |
Sep 15 '26 |
Option Exercise |
12.21 |
76,452 |
933,479 |
1,602,310 |
| Hoge Stephen | Officer |
Sep 14 '26 |
Proposed Sale |
144.13 |
40,294 |
5,807,746 |
0 |
| Hoge Stephen | President |
Sep 14 '26 |
Sale |
144.13 |
40,294 |
5,807,574 |
1,525,858 |
| Mock James M | Chief Financial Officer |
Sep 10 '26 |
Sale |
134.49 |
34,836 |
4,685,094 |
59,375 |
| Mock James M | Chief Financial Officer |
Sep 10 '26 |
Option Exercise |
30.96 |
19,836 |
614,123 |
94,211 |
| Mock James M | Officer |
Sep 10 '26 |
Proposed Sale |
134.49 |
34,836 |
4,685,094 |
0 |
| Klinger Shannon Thyme | Chief Legal Officer |
Sep 01 '26 |
Option Exercise |
30.96 |
3,471 |
107,462 |
77,600 |
| Klinger Shannon Thyme | Chief Legal Officer |
Sep 01 '26 |
Sale |
139.95 |
3,471 |
485,766 |
74,129 |
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):